Skip to main content
Erschienen in: International Urology and Nephrology 8/2023

23.02.2023 | COVID-19 | Nephrology - Original Paper

Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections

verfasst von: Htay Htay, Marjorie Wai Yin Foo, Mathini Jayaballa, David W. Johnson, Elizabeth Ley Oei, Ban Hock Tan, Wei Wang, Sin Yan Wu, Chieh Suai Tan

Erschienen in: International Urology and Nephrology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There were discrete outbreaks of SARS-CoV-2 infection in 2021 (Delta wave) and 2022 (Omicron wave) in Singapore, which affected patients receiving peritoneal dialysis (PD).

Methods

This study included all PD patients with COVID-19 infection from a single center between October 2021 and March 2022. The clinical presentation, management and outcomes of patients during the Delta and Omicron outbreaks were compared.

Results

A total of 44 PD patients developed SARS-CoV-2 infection (23 during the Delta wave and 21 during the Omicron wave): median age 66 (60.5–68.5) years, male (63.6%), Chinese ethnic (77.3%), diabetes mellitus (56.8%), and cardiovascular disease (45.5%). Approximately, 93.2% received two doses of the mRNA COVID-19 vaccine. Cough (81.8%) and fever (54.5%) were common presenting symptoms. Chest radiography showed ground glass opacity in 23.5% of patients, consolidation in 55.6%, and bilateral lung involvement in 33.3%. Eleven patients (25.6%) received antiviral therapy (Remdesivir), 7 (16.3%) received steroid, and 4 (9.3%) received monoclonal antibodies. Patients infected during the Delta wave were more likely to be hospitalized (73.9 vs 14.3%; p < 0.001) and receive antiviral therapy (39.1 vs 10.0%; p = 0.03) than those during the Omicron wave. The overall mortality rate was 11.4%, with significantly higher mortality during the Delta wave than during the Omicron wave (21.7 vs 0%; p = 0.03).

Conclusions

The mortality rate was high among infected PD patients during Delta wave of COVID-19 infection. However, during the Omicron wave, most infected patients were treated in the community with favorable outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A et al (2021) COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant 36(11):2094–2105CrossRefPubMedPubMedCentral Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A et al (2021) COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant 36(11):2094–2105CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Sachdeva M, Uppal NN, Hirsch JS, Ng JH, Malieckal D, Fishbane S et al (2020) COVID-19 in hospitalized patients on chronic peritoneal dialysis: a case series. Am J Nephrol 51(8):669–674 CrossRefPubMed Sachdeva M, Uppal NN, Hirsch JS, Ng JH, Malieckal D, Fishbane S et al (2020) COVID-19 in hospitalized patients on chronic peritoneal dialysis: a case series. Am J Nephrol 51(8):669–674 CrossRefPubMed
5.
Zurück zum Zitat Yavuz D, Karagöz Özen DS, Demirağ MD (2022) COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis. Int Urol Nephrol 54(10):2713–2718CrossRefPubMedPubMedCentral Yavuz D, Karagöz Özen DS, Demirağ MD (2022) COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis. Int Urol Nephrol 54(10):2713–2718CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kazancıoğlu R, Öztürk S, Turgutalp K, Gürsu M, Arıcı M, Oruç A et al (2022) COVID-19 infection in peritoneal dialysis patients: a comparative outcome study with patients on hemodialysis and patients without kidney disease. Turkish J Nephrol 31(1):33–42CrossRef Kazancıoğlu R, Öztürk S, Turgutalp K, Gürsu M, Arıcı M, Oruç A et al (2022) COVID-19 infection in peritoneal dialysis patients: a comparative outcome study with patients on hemodialysis and patients without kidney disease. Turkish J Nephrol 31(1):33–42CrossRef
7.
Zurück zum Zitat Chen J-J, Tao LH, Tian Y-C, Lee C-C, Fan P-C et al (2021) Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2131749–e2131749CrossRefPubMedPubMedCentral Chen J-J, Tao LH, Tian Y-C, Lee C-C, Fan P-C et al (2021) Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2131749–e2131749CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S et al (2021) Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int 99(6):1490–1492CrossRefPubMedPubMedCentral Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S et al (2021) Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int 99(6):1490–1492CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Billany RE, Selvaskandan H, Adenwalla SF, Hull KL, March DS, Burton JO et al (2021) Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms. Kidney Int 99(6):1492–1494CrossRefPubMedPubMedCentral Billany RE, Selvaskandan H, Adenwalla SF, Hull KL, March DS, Burton JO et al (2021) Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms. Kidney Int 99(6):1492–1494CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, del Mosquera MM, Marcos MA, Egri N et al (2021) Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis 78(4):571–581CrossRefPubMedPubMedCentral Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, del Mosquera MM, Marcos MA, Egri N et al (2021) Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis 78(4):571–581CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M et al (2021) Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol 32(9):2153–2158CrossRefPubMedPubMedCentral Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M et al (2021) Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol 32(9):2153–2158CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB (2021) Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int 99(6):1494–1496CrossRefPubMedPubMedCentral Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB (2021) Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int 99(6):1494–1496CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B et al (2021) High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 36(9):1704–1709CrossRefPubMed Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B et al (2021) High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 36(9):1704–1709CrossRefPubMed
14.
Zurück zum Zitat Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D et al (2021) Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study. Nephrol Dial Transplant 36(7):1347–1349CrossRef Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D et al (2021) Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study. Nephrol Dial Transplant 36(7):1347–1349CrossRef
15.
Zurück zum Zitat Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J et al (2020) Presentation and outcomes of patients with ESKD and COVID-19. J Am Soc Nephrol 31(7):1409–1415CrossRefPubMedPubMedCentral Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J et al (2020) Presentation and outcomes of patients with ESKD and COVID-19. J Am Soc Nephrol 31(7):1409–1415CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira IATM et al (2021) SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature 599(7883):114–119CrossRefPubMedPubMedCentral Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira IATM et al (2021) SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature 599(7883):114–119CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Rodríguez-Espinosa D, Broseta JJ, Maduell F, Bedini JL, Vera M (2021) Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients. Kidney Int 100(2):476–477CrossRefPubMedPubMedCentral Rodríguez-Espinosa D, Broseta JJ, Maduell F, Bedini JL, Vera M (2021) Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients. Kidney Int 100(2):476–477CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Labriola L, Scohy A, Seghers F (2021) A longitudinal, 3-month serologic assessment of SARS-CoV-2 infections in a Belgian hemodialysis facility. Am Soc Nephrol 16(4):613–614CrossRef Labriola L, Scohy A, Seghers F (2021) A longitudinal, 3-month serologic assessment of SARS-CoV-2 infections in a Belgian hemodialysis facility. Am Soc Nephrol 16(4):613–614CrossRef
20.
Zurück zum Zitat Asan A, Demirhan H, Sorkun HÇ, Özkan S, Aydın M, Akın D et al (2017) Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol 49(10):1845–1850CrossRefPubMed Asan A, Demirhan H, Sorkun HÇ, Özkan S, Aydın M, Akın D et al (2017) Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol 49(10):1845–1850CrossRefPubMed
21.
Zurück zum Zitat Htay H, Wong PMPK, Choo RER, Dawood US, Foo MWY, Jayaballa M et al (2020) Strategies for management of peritoneal dialysis patients in Singapore during COVID-19 pandemic. Ann Acad Med Singapore 49(12):1025–1028CrossRefPubMed Htay H, Wong PMPK, Choo RER, Dawood US, Foo MWY, Jayaballa M et al (2020) Strategies for management of peritoneal dialysis patients in Singapore during COVID-19 pandemic. Ann Acad Med Singapore 49(12):1025–1028CrossRefPubMed
22.
Zurück zum Zitat Alfano G, Fontana F, Ferrari A, Guaraldi G, Mussini C, Magistroni R et al (2020) Peritoneal dialysis in the time of coronavirus disease 2019. Clin Kidney J 13(3):265–268PubMedPubMedCentral Alfano G, Fontana F, Ferrari A, Guaraldi G, Mussini C, Magistroni R et al (2020) Peritoneal dialysis in the time of coronavirus disease 2019. Clin Kidney J 13(3):265–268PubMedPubMedCentral
Metadaten
Titel
Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections
verfasst von
Htay Htay
Marjorie Wai Yin Foo
Mathini Jayaballa
David W. Johnson
Elizabeth Ley Oei
Ban Hock Tan
Wei Wang
Sin Yan Wu
Chieh Suai Tan
Publikationsdatum
23.02.2023
Verlag
Springer Netherlands
Schlagwort
COVID-19
Erschienen in
International Urology and Nephrology / Ausgabe 8/2023
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03496-2

Weitere Artikel der Ausgabe 8/2023

International Urology and Nephrology 8/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.